Patent Application
20120196919
This invention relates to a method for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and atherosclerosis.
The protein kinase C family is a group of serine/threonine kinases that is comprised of twelve related isoenzymes. These kinases are expressed in a wide range of tissues and cell types. Its members are encoded by different genes and are sub-classified according to their requirements for activation. The classical PKC enzymes (cPKC) require diacylglycerol (DAG), phosphatidylserine (PS) and calcium for activation. The novel PKC's (nPKC) require DAG and PS but are calcium independent. The atypical PKC's (aPKC) do not require calcium or DAG.
PKC-theta is a member of the nPKC sub-family. It has a restricted expression pattern, found predominantly in T cells and skeletal muscle. Upon T cell activation, an immunological synapse (IS) composed of supramolecular activation clusters (SMACs) forms at the site of contact between the T cell and antigen presenting cell (APC). PKC-theta is the only PKC isoform found to localize at the SMAC (C. Monks et al., Nature, 1997, 385, 83), placing it in proximity with other signaling enzymes that mediate T cell activation processes. In another study, (G. Baier-Bitterlich et al., Mol. Cell. Biol., 1996, 16, 842) the role of PKC-theta in the activation of AP-1, a transcription factor important in the activation of the IL-2 gene, was confirmed. In unstimulated T cells, constitutively active PKC-theta stimulated AP-1 activity while in cells with dominant negative PKC-theta, AP-1 activity was not induced upon activation by PMA. Other studies showed that PKC-theta, via activation of IκB kinase beta, mediates activation of NF-κB induced by T cell receptor/CD28 co-stimulation (N. Coudronniere et al., Proc. Nat. Acad. Sci. U.S.A., 2000, 97, 3394; X. Lin et al., Moll. Cell. Biol., 2000, 20, 2933). Proliferation of peripheral T cells from PKC-theta knockout mice, in response to T cell receptor (TCR)/CD28 stimulation was greatly diminished compared to T cells from wild type mice. In addition, the amount of IL-2 released from the T cells was also greatly reduced (Z. Sun et al., Nature, 2000, 404, 402). Otherwise, the PKC-theta knockout mice seemed normal and were fertile.
The studies cited above and other studies confirm the critical role of PKC-theta in T cell activation and subsequent release of cytokines such as IL-2 and T cell proliferation (A. Altman et al., Immunology Today, 2000, 21, 567). Thus an inhibitor of PKC-theta would be of therapeutic benefit in treating immunological disorders and other diseases mediated by the inappropriate activation of T cells.
It has been well established that T cells play an important role in regulating the immune response (Powrie and Coffman, Immunology Today, 1993, 14, 270). Indeed, activation of T cells is often the initiating event in immunological disorders. Following activation of the TCR, there is an influx of calcium that is required for T cell activation. Upon activation, T cells produce cytokines, including as IL-2, leading to T cell proliferation, differentiation, and effector function. Clinical studies with inhibitors of IL-2 have shown that interference with T cell activation and proliferation effectively suppresses immune response in vivo (Waldmann, Immunology Today, 1993, 14, 264). Accordingly, agents that inhibit T lymphocyte activation and subsequent cytokine production are therapeutically useful for selectively suppressing the immune response in a patient in need of such immunosuppression and therefore are useful in treating immunological disorders such as autoimmune and inflammatory diseases.
US Patent Application Publication number US 2005/0124640, incorporated herein by reference, discloses compounds of formula (I) that are inhibitors of PKC-theta, useful for treating a variety of diseases mediated by PKC-theta including immunological diseases.
In a general aspect, the present invention is directed to a method of treating an immunological disorder or atherosclerosis in a patient comprising the treating blood from the patient with an inhibitor of PKC-theta ex vivo and then re-administering the treated blood to the patient.
In another aspect of the invention, the leukocyte fraction from the patient blood is isolated and treated with an inhibitor of PKC-theta ex vivo and then re-administered to the patient.
In another aspect of the invention, Treg cells from the patient blood are isolated and treated with an inhibitor of PKC-theta ex vivo and then re-administered to the patient.
In another aspect of the invention, Treg cells from the patient blood are isolated, induced to grow to generate larger numbers of Treg cells and treated with an inhibitor of PKC-theta ex vivo and then re-administered to the patient.
In another aspect of the invention, the PKC-theta inhibitor is a compound of formula (I)
wherein R1, R2 and R3 are as defined herein.
In another aspect, the immunological disorder is selected from inflammatory diseases, autoimmune diseases, organ and bone marrow transplant rejection and other disorders associated with T cell mediated immune response, including acute or chronic inflammation, allergies, contact dermatitis, psoriasis, rheumatoid arthritis, multiple sclerosis, type I diabetes, inflammatory bowel disease, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, graft versus host disease (and other forms of organ or bone marrow transplant rejection) and lupus erythematosus.
a-c
Inhibition of PKC-theta by specific inhibitor, Compound Ia, up-regulates the suppressive function of CD4+CD25+ Treg cells in vitro.
Treg cells and CD4+CD25− Teff (non-Treg) cells were treated with Compound Ia at 0.001-1 microM (a-b) for 30 min, or at 1 microM for 0-60 min (c). Treated cells were mixed with CD4+CD25− T (Teff) cells at 1:9 ratio and plated on immobilized anti-CD3 mAb. The supernatants were analyzed for IFN-gamma after 24-48 hours (a and c). Cell proliferation was determined after 96 hours (b). Average of four different experiments is shown.
Up-regulation of suppressive function by inhibitors of PKC-theta correlates with their IC50's
Treg were treated with 1 microM PKC-theta inhibitors with different IC50 values as indicated on graph. Treated cells were mixed with CD4+CD25− T (Teff) cells at 1:9 ratio and plated on immobilized anti-CD3 mAb. The supernatants were analyzed for IFN-gamma after 24-48 hours. An average of four different experiments is shown. As shown in the graph, the enhancement of suppressive effect on IFN-gamma secretion generally correlates with the potency of the inhibitors.
Treg were transfected with silent RNA targeting PKC-theta, or with control silent RNA and plated on anti-CD3 mAb. After 48 hours the PKC-theta expression was measured by Western blot analysis.
Inhibition of PKC-theta by siRNA up-regulates the suppressive function of CD4+CD25+ Treg cells in vitro.
Treated Treg and non-Treg, or siRNA-transfected Treg were mixed with CD4+CD25− T (Teff) cells at 1:9 ratio and plated on immobilized anti-CD3 mAb. The supernatants were analyzed for IFN-gamma after 24-48 hours. An average of four different experiments is shown.
a-5d
Treatment with PKC-theta inhibitor up-regulates Treg function in vivo.
Colitis was induced in C57BL/10.PL TCR alpha−/−beta−/− mice as described in Methods summary. 5a—numbers of mice were 5 (PBS), 8 (Teff), 7 (Teff/Treg control), 7 (Teff/Treg PKC-theta inhibitor). 5b-Histology slides of distal colon for the different groups. Normal histology is observed in PKC-theta treated mice. 5c, 5d-Freshly purified Treg from healthy donors and RA patients were treated or not with PKC-theta inhibitor for 30 min at 1 microM, washed three times, mixed with CD4+CD25− T cells at ratio 1:3, and plated on anti-CD3 mAb. The supernatants were analyzed for IFN-gamma after 24-48 hours. Combined data of three independent experiments are presented. % Treg-mediated inhibition was calculated as: 1−level of IFN-gamma in presence of Treg/level of IFN-gamma in absence of Treg)φ100%. P values were calculated by t-test.
CD4+CD25+ regulatory T cells (Tregs) suppress the function of CD4+ and CD8+ effector cells (Teff) through an antigen receptor and cell contact mechanism. Recent studies demonstrated that TCR activation is required for the ability of the Treg cells to inhibit proliferation of responder CD4+CD25− T cells in vitro (A. M. Thornton et al., Eur. J. Immunol, 2004, 34, 366). We investigated whether inhibition of PKC-theta may affect the suppressive function of human CD4+CD25+ Treg cells in vitro. For this purpose, we treated CD4+CD25+ Treg or CD4+CD25− Teff cells (Treg or non-Treg respectively in
Treatment of Treg cells with analogs of PKC-theta inhibitors with different IC50 values demonstrated the correlation of the suppressive effect with potency of the inhibitor. The PKC-theta inhibitors with IC50≦1 nM significantly up-regulated their suppressive function (
To confirm the conclusion that inhibition of PKC-theta up-regulates the suppressive activity of human Treg, we specifically silenced PKC-theta gene expression using RNA interference (K. K. Srivastava et al., J. Biol. Chem., 2004, 279, 29911). This treatment abrogated the PKC-theta expression in Treg cells by 80% (
Next, we determined the ability of PKC-theta inhibitor Ia to up-regulate Treg function in vivo using a colitis model in TCR alpha−/−beta−/− mice induced by transfer of effector CD4+CD25−CD45RB+ Teff cells (F. Powrie, et al., J. Exp. Med. 1996, 183, 2669). At a 1:4 ratio of Treg/Teff, PKC-theta inhibitor treated-CD4+CD25+ Treg cells provided nearly 100% protection of the recipient mice from colitis, as demonstrated by normal weigh gain and normal histology of the distal colon in 7 of 8 mice (
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that ultimately leads to the destruction of joint architecture. Recent studies in RA patients have suggested that the function of CD4+CD25+ Treg cells is impaired (Ehrenstein, M. R., et al., J. Exp. Med., 2004, 200, 277). By using CD4+CD25+ Treg cells, purified from peripheral blood of 25 RA patients with different severities of disease we found that although Treg numbers were comparable with healthy donors, Treg cells demonstrated significantly reduced ability to suppress the production of IFN-gamma from autologous Teff cells compared to healthy donors (
The application of Treg based adoptive immunotherapy for the treatment of autoimmune diseases has recently become feasible due to improved methods to grow large numbers of Treg in vitro (see review by C. H. June and B. R. Blazar Seminars in immunology, 2006, 18, 78 and also Hippen, et al., Blood 2008, 112: 2847). Possible applications include treatment of Graft-versus-host disease, organ rejection and autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, rheumatoid arthritis and Type 1 diabetes. Isolation and ex vivo expansion of Treg populations for use in adoptive immunotherapy is documented in the literature and known in the art (see also US 2009/0010950 A1, incorporated herein by reference), In the studies above, we have shown for the first time that the inhibition of PKC-theta has potential in Treg based adoptive immunotherapy.
Treg cells have also been reported to have an inhibitory effect on atherosclerosis (P. Aukrust et al., Curr. Atherosclerosis Reports, 2008, 10, 236) and have shown to have an inhibitory effect in a mouse model of atherosclerosis (H. Ait-Oufella et al., Nature Medicine, 2006, 12, 178). Thus, inhibition of PKC-theta in Treg cells which has been shown to boost the suppressive effects of this cell population, should have a beneficial effect in atherosclerosis.
In one embodiment, blood is isolated from a patient having an immunological disorder, the blood is treated ex vivo with an inhibitor of PKC-theta and then infused back into the patient.
In another embodiment, blood is isolated from a patient having atherosclerosis, the blood is treated ex vivo with an inhibitor of PKC-theta and then infused back into the patient.
In another embodiment, the leukocyte fraction of the blood is isolated from a patient having an immunological disorder, the leukocyte fraction is treated ex vivo with an inhibitor of PKC-theta and then infused back into the patient.
In another embodiment, blood is isolated from a patient having an immunological disorder, the Treg cells are isolated and expanded ex vivo, treated with an inhibitor of PKC-theta and then infused back into the patient.
In another embodiment, blood is isolated from a patient having atherosclerosis, the Treg cells are isolated and expanded ex vivo, treated with an inhibitor of PKC-theta and then infused back into the patient.
In another embodiment, peripheral blood mononucular cells and T-cells are separated by plasmapheresis from blood isolated from a patient having an immunological disorder and are treated with an inhibitor of PKC-theta and then infused back into the patient.
In another embodiment, peripheral blood mononucular cells and T-cells are separated by plasmapheresis from blood isolated from a patient having atherosclerosis and are treated with an inhibitor of PKC-theta and then infused back into the patient.
In another embodiment, the PKC-theta inhibitor is a compound of formula (I)
R1 is aryl-C1-4alkyl or heteroaryl-C1-4alkyl, wherein in each of the C1-4alkyl groups a methylene group may optionally be replaced by —NHC(O)— or —C(O)NH—, and wherein each of the C1-4alkyl groups is optionally substituted by an oxo group or one or more C1-3alkyl groups wherein two alkyl substituents on the same carbon atom of a C1-4alkyl group may optionally be combined to form a C2-5 alkylene bridge, and wherein the aryl group is optionally substituted on adjacent carbon atoms by a C3-6alkylene bridge group wherein a methylene group is optionally replaced by an oxygen, sulfur or —N(R6)—;
or R1 has the following structure:
wherein x and y are independently 0, 1, 2 or 3, provided that x+y is 2 to 3, and z is 0 or 1;
wherein “heteroaryl” is defined as pyridyl, furyl, thienyl, pyrrolyl, imidazolyl, or indolyl;
wherein each R1 group is optionally substituted by one or more of the following groups: C1-6alkyl, Cl, Br, F, nitro, hydroxy, CF3, —OCF3, —OCF2H, —SCF3, C1-4alkyloxy, C1-4alkylthio, phenyl, benzyl, phenyloxy, phenylthio, aminosulfonyl, or amino optionally substituted by one or two C1-3alkyl groups;
R2 is selected from the following groups:
wherein:
n is an integer from 5 to 7;
p is an integer from 1 to 2;
q is an integer from 1 to 2;
R4 and R5 are each independently selected from hydrogen, C1-6alkyl, arylC1-6alkyl, or amidino;
R6 is hydrogen;
R3 is Br, Cl, F, cyano or nitro;
or a tautomer, pharmaceutically acceptable salt or solvate thereof.
In another embodiment, the PKC-theta inhibitor is any inhibitor of PKC-theta which is disclosed in US Patent Application Publication number US 2005/0124640, all generic and specific embodiments of which are herein incorporated by reference.
In another embodiment, the PKC-theta inhibition is achieved by siRNA or shRNA mediated suppression of PKC-theta and either (a) the siRNA or shRNA is targeted to cells that include Tregs ex vivo followed by infusion of the treated cells into patients or (b) the siRNA or shRNA is directly administered to the patient. In a specific embodiment blood is isolated from a patient, the Treg cells are isolated and expanded ex vivo, treated with an siRNA or shRNA and then infused back into the patient.
Thus, in a specific embodiment the PKC-theta inhibition is achieved by siRNA or shRNA mediated suppression of PKC-theta and the method comprises treating blood from the patient with siRNA or shRNA ex vivo and then re-administering the treated blood to the patient. In a more specific embodiment, the Treg cells from the patient blood are isolated and treated with siRNA or shRNA ex vivo and then re-administered to the patient.
In another embodiment the immunological disorder is selected from psoriasis, rheumatoid arthritis, multiple sclerosis, type I diabetes, inflammatory bowel disease, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, graft versus host disease (and other forms of organ or bone marrow transplant rejection), systemic lupus erythematosus
CD4+CD25+ Treg and CD4+CD25− Teff cells were purified from the peripheral blood of healthy human donors or from 25 patients with Rheumatoid arthritis in different stages (accordingly to disease activity score (DAS)) as described in the literature M. L. Prevoo, et al., Arthritis and rheumatism, 1995, 38, 44; A. Zanin-Zhorov, et al., J. Clin. Invest, 2006, 116, 2022). In co-culture experiments, CD4+CD25+ Teff cells were treated or not, washed, and added at different ratios (1:9, 1:3 or 1:1) to CD4+CD25− Teff cells. The cells were co-cultured on anti-CD3 mAb pre-coated 24-well plates for 24-48 hr (cytokine secretion), or 96 hr (proliferation). Cytokine secretion was determined by ELISA as previously described A. Zanin-Zhorov, et al., ibid., 2006), using Human IFN-gamma Cytose™ (Biosource; Camarillo, Calif.). Proliferation was assessed by Alamar Blue™ assay (Invitrogen) as previously described (S. A. Ahmed, et al., J. immunological Methods, 1994, 170, 211-224).
SiRNA duplexes (siRNAs) were synthesized and purified by Qiagen Inc as described in the literature (K. K. Srivastava, et al., J. Biol. Chem. 2004, 279, 29911). The PKC-theta target sequences were: siRNA1 (5′-AAACCACCGTGGAGCTCTACT-3′) and siRNA2 (5′-AAGAGCCCGACCTTCTGTGAA-3′); control siRNA was purchased from Qiagen (1027281). Transfections of freshly purified T cells were performed using the human T cell Nucleofector kit (Amaxa Biosystems). Transfected cells were cultured in RPMI 1640 containing 10% FCS on immobilized anti-CD3 antibodies for 48-72 hours. Tranfection efficiency was controlled by evaluating PKC-theta levels using Western Blot analysis.
For T cell transfer model of colitis, we intravenously injected C57BL/10.PL TCR alpha−/−beta−/− mice with 5×105 sorted CD4+CD25−CD45RB+ T cells alone or in combination with 0.125×105 of CD4+CD25+ T cells that were pretreated or not as indicated. Disease progression was monitored by body weight loss, diarrhea and histology analysis as previously described (F. Powrie, et al., J. Exp. Med. 1996, 183, 2669). P values were determined by Mann-Whitney test or two-tailed t-test by using the GraphPad Prism software (San Diego, Calif.).
The PKC-theta inhibitors used and their IC50's are shown in Table 1 below. The preparation of these compounds and the luciferase assay used to determine the IC50 for inhibition of the kinase activity of PKC-theta are described in US Patent Application Publication number 2005/0124640. For the in vitro and ex vivo assays above, compounds were dissolved in DMSO. T cells were pretreated with indicated concentrations of the inhibitors or DMSO control for 30 min at 37° C. and washed three times.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US10/32707 | 4/28/2010 | WO | 00 | 4/20/2012 |
| Number | Date | Country | |
|---|---|---|---|
| 61173237 | Apr 2009 | US |
